Source: Cardiovascular Business

Hydroxychloroquine is associated with reducing ICU admissions among hospitalized COVID-19 patients, according to new findings published in the International Journal of Infectious Diseases. Chloroquine, however, was not found to have such an effect.

Hydroxychloroquine and chloroquine are antimalarial drugs that have been at the center of dozens of controversies and debates since the beginning of the COVID-19 pandemic. Early evidence suggested one, or even both, of the drugs may be a game-changer in the treatment of COVID-19. However, details related to poor cardiovascular outcomes such as arrhythmias—and some other concerning findings—led many medical professionals to urge extreme caution.

This latest study included data from more than 1,000 adult COVID-19 patients who received treatment at one of 14 hospitals in the Netherlands from Feb. 28 to April 1.   

“Based on the available evidence present at the start of the outbreak, a Dutch treatment guideline was developed,” wrote first author A.J.J. Lammers, MD, PhD, of Isla Hospital in Zwolle, the Netherlands, and colleagues. “Off-label use of both hydroxychloroquine and chloroquine was given as a treatment option; however, the guidelines did not endorse either treatment in particular. Consequently, hospitals decided independently on a treatment protocol with either hydroxychloroquine or chloroquine, or to give no treatment. This policy created a unique situation for comparing the efficacy of hydroxychloroquine and chloroquine with no treatment in hospitalized non-ICU patients with a reduction of potential bias by indication.”

Overall, the study revealed that the medications were not related to any significant changes to patient mortality. Hydroxychloroquine, however, was associated with a 53% reduction of being transferred to the ICU. Patients treated with chloroquine did not experience the same effect.

“This finding suggests that starting early treatment with hydroxychloroquine (within one day of admission) on the regular COVID-ward might prevent progression to critical respiratory illness,” the authors wrote. “This is consistent with the suggestion that hydroxychloroquine treatment reduces the risk of disease progression more effectively earlier in the course of the disease. This holds true for many other viral infections such as influenza and herpes simplex, where treatment must be initiated soon after onset of symptoms in order to confer benefit. However, treatment with hydroxychloroquine before onset of symptoms did not prevent COVID-19, as was demonstrated in a randomized controlled trial investigating post-exposure use of hydroxychloroquine.”







Related:

Choose Truth and Choose Life

How hydroxychloroquine works at the cellular level

C19study.com update: Now 88 international studies (51 peer reviewed) show positive hydroxychloroquine treatment outcomes

Belgium Study: Low-dose Hydroxychloroquine Therapy and Mortality (Lowered) in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »